The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator

被引:188
作者
Kim, Ji-Young [1 ,2 ]
Kim, Jin-Ki [1 ]
Park, Jeong-Sook [3 ,4 ]
Byun, Youngro [2 ]
Kim, Chong-Kook [1 ,5 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Lab Excellency Drug & Gene Delivery, Seoul 151742, South Korea
[2] Seoul Natl Univ, Coll Pharm, Lab Drug & Macromol Delivery, Seoul 151742, South Korea
[3] Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea
[4] Chungnam Natl Univ, Inst Drug Res & Dev, Taejon 305764, South Korea
[5] Inje Univ, Dept Pharmaceut Engn, Gimhae Gyungnam 621749, South Korea
关键词
Tissue plasminogen activator; Half-life; Prolong; Liposomes; PEG; Fibrinolysis; DRUG-DELIVERY SYSTEM; T-PA; ACCELERATED THROMBOLYSIS; STABILITY; STREPTOKINASE; NANOPARTICLES; PERMEABILITY; EFFICIENCY; VESICLES; DESIGN;
D O I
10.1016/j.biomaterials.2009.07.021
中图分类号
R318 [生物医学工程];
学科分类号
100103 [病原生物学];
摘要
Tissue plasminogen activator (tPA), a widely used thrombolytic agent, has an application limit due to short half-life. To prolong the half-life of tPA, liposomes composed of egg phosphatidylcholine (EPC), cholesterol (CHOL) and sodium cholesterol-3-sulfate (CS) were prepared by lipid film method. In addition, distearolyphosphatidyl ethanolamine-N-poly(ethylene glycol) 2000 (DSPE-PEG 2000) was included to give steric barrier to liposomes. Physicochemical characteristics such as particle size, zeta potential, entrapment efficiency and long-term storage stability at 4 degrees C were investigated. The fibrinolytic activity of tPA-loaded in liposomes was confirmed by fibrin clot lysis assay. In vivo pharmacokinetic properties of tPA and the effect of PEG on the blood circulation of tPA-loaded in liposomes in circulation were also evaluated. Both conventional liposomes (EPCL) and PEGylated liposomes (EPC-PEGL) were proper as an injectable formulation with small particle size. Loading process of tPA into liposomes did not alter fibrinolytic activity of intact tPA. Encapsulation of tPA into EPCL and EPC-PEGL prolonged half-life of tPA by 16 and 21 folds compared with free tPA, respectively. Therefore, the use of liposomes could prolong the circulation lifetimes and longevity effect of liposomes on tPA was increased by PEG. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5751 / 5756
页数:6
相关论文
共 38 条
[1]
PHARMACOKINETICS OF STEALTH VERSUS CONVENTIONAL LIPOSOMES - EFFECT OF DOSE [J].
ALLEN, TM ;
HANSEN, C .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1068 (02) :133-141
[2]
*AZ ART, US ZET POT MEAS STUD
[3]
Plasminogen activators: A comparison [J].
Baruah, DB ;
Dash, RN ;
Chaudhari, MR ;
Kadam, SS .
VASCULAR PHARMACOLOGY, 2006, 44 (01) :1-9
[4]
BERGER H, 1988, BLOOD, V71, P1641
[5]
BERGSTRAND N, 2003, THESIS UPPSALA U SWE
[6]
Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles [J].
Chung, Tze-Wen ;
Wang, Shoei-Shen ;
Tsai, Wei-Jain .
BIOMATERIALS, 2008, 29 (02) :228-237
[7]
COLLEN D, 1994, MOL BASIS BLOOD DIS, P725
[8]
DRUG-LADEN LIPOSOMES IN ANTITUMOR THERAPY AND IN THE TREATMENT OF PARASITIC DISEASES [J].
CROMMELIN, DJA ;
NASSANDER, UK ;
PEETERS, PAM ;
STEERENBERG, PA ;
DEJONG, WH ;
ELING, WMC ;
STORM, G .
JOURNAL OF CONTROLLED RELEASE, 1990, 11 (1-3) :233-243
[9]
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding [J].
Dos Santos, Nancy ;
Allen, Christine ;
Doppen, Anne-Marie ;
Anantha, Malathi ;
Cox, Kelly A. K. ;
Gallagher, Ryan C. ;
Karlsson, Goran ;
Edwards, Katanna ;
Kenner, Gail ;
Samuels, Lacey ;
Webb, Murray S. ;
Bally, Marcel B. .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2007, 1768 (06) :1367-1377
[10]
Drug carriers in pharmaceutical design: Promises and progress [J].
Dutta, Ranjna C. .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (07) :761-769